.png)
ChromoGenics Q3 2023: Robust order intake and cost reduction continue. But weak sales in the quarter (Redeye)
2023-11-30 09:11
Redeye comments on ChromoGenics Q3 2023 report. The cost reduction efforts made throughout the quarter resulted in a smaller loss than anticipated. Although sales were significantly lower, a robust order intake provides a positive outlook
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se